COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Prospective, multi-centre, randomized, open-label, parallel comparisons to evaluate
- the incidence of bleedings (COSTA-Bleed) and
- the incidence of ischemic and bleeding events (COSTA-Outcome) following a therapy with
the abluminal sirolimus coated bio-engineered stent (COMBO stent) in association with
short-term single antiplatelet therapy as compared to a guidelines-based strategy in
patients with coronary artery disease with an indication for chronic oral anticoagulant
therapy.
Phase:
Phase 4
Details
Lead Sponsor:
IHF GmbH - Institut für Herzinfarktforschung
Collaborator:
OrbusNeich
Treatments:
Anticoagulants Clopidogrel Dabigatran Rivaroxaban Sirolimus Ticlopidine Vitamin K Vitamins